Clinical trials: Obese Subjects
Obesity
Study to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects
The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.
- Trial name
- NCT07337174
- Testing
- HUC2-676, HUC2-676-R
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Obesity
The Safety and Efficacy of the ReShape Intragastric Balloon in Obese Subjects
The study evaluated the safety and efficacy of the ReShape Intragastric Balloon as an adjunct to diet and exercise in obese patients compared with diet and exercise alone.
- Trial name
- NCT01061385
- Testing
- ReShape Intragastric Balloon, Control Arm
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ReShape Lifesciences
Obesity
A Study to Determine the Effects of TM30339 on Weight Loss in Obese Individuals.
The purpose of this study is to determine the effects of TM30339 on weight loss in obese individuals after 28 days dosing.
- Trial name
- NCT00746824
- Volunteers
- 192 people
- Sponsor
- 7TM Pharma A/S
Acute Kidney Injury
PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects
The main purpose of this trial is to demonstrate the safety, tolerability and pharmacokinetics (PK) of CXA-10 and its metabolite(s) administered as multiple ascending oral doses over 14 days to healthy obese male volunteers.
- Trial name
- NCT02460146
- Testing
- CXA-10
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Complexa, Inc.
Obese
Pharmacodynamics and Pharmacokinetics of Different Glucose Bead Formulations in Obese Healthy Subjects
The goal of this clinical study was to assess pharmacodynamics (PD) and pharmacokinetics (PK) of different Glucose beads formulations in obese healthy subjects under fasting condition. The study was designed in 2 parts.
- Trial name
- NCT05737927
- Testing
- Glucose 8 g coated beads (47% w/w), Glucose 12 g coated beads (47% w/w), Glucose 16 g coated beads (47% w/w)
- Where
- Romania
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Aphaia Pharma US LLC
Obstructive Sleep Apnea (OSA)
Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy
This study is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of GZR18 injection in obese subjects with moderate to severe obstructive sleep apnea…
- Trial name
- NCT07493057
- Testing
- GZR18 injection
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Obesity
Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss
Multiple pathways including peripheral and central hormones and neurotransmitters are involved in the regulation of food intake and body weight. One of the most studied pathways involves the melanocortin receptor.
- Trial name
- NCT00779519
- Testing
- TTP435
- Where
- 12 sites in United States, Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- vTv Therapeutics
Obesity
The ePass Clinical Trial for the Treatment of Obese Subjects
To evaluate the safety and efficacy of the endoscopically implanted ValenTx EndoPass™ System for treatment of adults with severe obesity.
- Trial name
- ePass (NCT02954016)
- Testing
- ePass
- Where
- 2 sites in Argentina, Mexico
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- ValenTx, Inc.
Obesity
Effect of a Novel Nutraceutical on Weight Loss and Weight Maintenance in Obese Subjects
The purpose of this 2-stage intervention study is to investigate the effect of a novel nutraceutical (containing tetrahydro iso-alpha acids derived from hops) on weight loss and weight loss maintenance in obese participants.
- Trial name
- NCT01656681
- Testing
- THIAA
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- MetaProteomics LLC
Type 2 Diabetes (T2D)
Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)
This study will test the safety and tolerability of omarigliptin. It is hypothesized that administration of once-weekly omarigliptin in obese but otherwise healthy participants, and in obese participants with Type 2 diabetes…
- Trial name
- NCT01088711
- Testing
- Omarigliptin
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Obesity
Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity
The purpose of this study is to determine whether CP-741,952 is effective in the treatment of obesity and to determine 12 week safety and toleration.
- Trial name
- NCT00367783
- Testing
- CP-741,952
- Where
- 5 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Pfizer
Heart Failure With Preserved Ejection Fraction
HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction
This was a multicenter, randomized, double-blind, placebo-parallel-controlled Phase II clinical study to evaluate the efficacy and safety of HRS9531 Injection compared to placebo in obese subjects with heart failure with…
- Trial name
- NCT06391710
- Testing
- HRS9531
- Where
- China
- Volunteers
- 203 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity
Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population
The primary objective of this study was to evaluate the efficacy and the safety of sibutramine vs. placebo in combination with a hypocaloric diet on weight-loss in overweight and obese Malaysian subjects.
- Trial name
- NCT00677391
- Testing
- Sibutramine
- Volunteers
- 103 people
- Sponsor
- Abbott
Type 2 Diabetes Mellitus (T2DM)
Multiple Dose Study Of PF-05231023 In Obese Adult Subjects
This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-05231023.
- Trial name
- NCT01923389
- Testing
- 100 mg PF-05231023
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
Obesity
Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects
The hypothesis of this study is that up to 150 mg of sertraline and up to 3 mg of telenzepine will be safe, tolerable, and have the effect of suppressing appetite, when taken in combination daily by mouth by healthy, overweight…
- Trial name
- NCT01155531
- Testing
- Sertraline plus Telenzepine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Theracos
Hypothalamic Injury-induced Obesity (HIO)
48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)
Double-blind, randomized, placebo-controlled, single- center study followed by an open-label extension period. The study will have two parts: Part 1: 24 weeks double-blind treatment (DB), followed by Part 2: 24 weeks open-label…
- Trial name
- NCT03845075
- Testing
- Tesofensine/Metoprolol
- Where
- Denmark
- Volunteers
- 21 people
- Sponsor
- Saniona
Metabolism and Nutrition Disorder, Obesity
A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity
This trial is conducted in the United States of America. The aim of the trial is to investigate Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects being overweight or with obesity
- Trial name
- NCT02835235
- Testing
- NNC9204-0530
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Study That Will Evaluate Ketogenesis and Glucose-Dependent Insulin Secretion Methodologies in Healthy Male Subjects (MK-0000-159)(COMPLETED)
This study will test the hypotheses that a single dose of oxyntomodulin (OXM) will be neutral or better than placebo in lowering ambient glucose levels during a graded glucose infusion (GGI) and that a single dose of OXM will…
- Trial name
- NCT01055340
- Testing
- Oxyntomodulin (OXM), Comparator: Oxyntomodulin (OXM)
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Overweight, Obesity
A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function
The study looks at the blood levels of a new study medicine in people with normal and impaired kidney function. Participants will get the study medicine called NNC0174-0833.
- Trial name
- NCT04209049
- Testing
- NNC0174-0833
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects
The purpose of this study is to investigate the amount of metabolites of ATL-962 in the blood and to investigate the effect of ATL-962 on the amount of fat that is excreted in the faeces in subjects who are obese
- Trial name
- NCT00148382
- Testing
- ATL-962
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Alizyme